Table 4

Sensitivity analysis: Cox proportional hazards model for analysis of drug retention of secukinumab versus an alternative TNFi after prior exposure to only one or two TNFis

MethodVariableHR95% CIP value
Propensity score basedSecukinumab versus TNFi1.000.61 to 1.650.99
Covariate adjustment Secukinumab versus TNFi 1.05 0.64 to 1.71 0.84
 Age1.010.99 to 1.030.28
 Female versus male sex1.661.10 to 2.510.02
 ASDAS1.200.86 to 1.670.28
 BASFI1.040.91 to 1.190.57
 BASMI0.990.81 to 1.200.88
 HLA-B27 positive versus negative1.070.71 to 1.590.75
 Enthesitis, yes versus no1.000.65 to 1.520.98
 Peripheral arthritis, yes versus no1.050.69 to 1.590.83
 Non-radiographic versus radiographic axspA1.420.77 to 2.630.26
 Ever psoriasis, yes versus no1.000.54 to 1.841.00
 Ever uveitis, yes versus no0.650.37 to 1.160.15
 Ever inflammatory bowel disease, yes versus no1.180.61 to 2.260.62
 Current smoking, yes versus no1.000.59 to 1.691.00
 BMI ≤25 kg/m2 versus BMI >25 kg/m2 1.170.80 to 1.700.42
 Reason for discontinuation of prior
 TNFi (other vs ineffectiveness)
0.890.61 to 1.300.55
 Third-line versus second-line bDMARDs0.780.52 to 1.160.22
  • HR for discontinuation of secukinumab versus TNFi is shown in bold as the result of main interest for both methods of analysis used in the whole axSpA population (n=291; 142 events).

  • ASDAS, Ankylosing Spondylitis Disease Activity Score; axSpA, axial spondyloarthritis; BASFI, Bath Ankylosing Spondylitis Functional Index; BASMI, Bath Ankylosing Spondylitis Metrology Index; bDMARD, biological disease-modifying antirheumatic drug; BMI, body mass index; HLA-B27, human leucocyte antigen B27; TNFi, tumour necrosis factor inhibitor.